Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine

Valneva SE announced promising results from its Phase 1 trial of the VLA1601, a second-generation Zika vaccine candidate. Conducted in the U.S., the trial included 150 participants aged 18 to 49. The vaccine showed safety and elicited strong immune responses with no safety concerns reported. Participants received two doses, with additional adjuvants like CpG 1018® and 3M-052-AF used in some cases.

The trial results highlighted improved immunogenicity, particularly in the double-adjuvant treatment groups, compared to the first-generation vaccine. VLA1601 development utilizes the platform of IXIARO®, Valneva's Japanese encephalitis vaccine. Despite positive results, Valneva's continued development of VLA1601 is contingent on receiving significant funding.